Few treatment options are available for patients with epidermal growth factor receptor (EGFR) mutation‐positive metastatic non‐squamous non‐small cell lung cancer (NSCLC) who failed treatment with EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs). This evidence concerns the gene EGFR and non-small cell lung carcinoma.